1. Huntexil® Phase III programme and restructuring of operationsProInvestor Life Science SeminarIT-universitetet, 5. oktober 2011 2. Forward looking disclaimerThis presentation…

1. Nicolas BernardPauline FlipoMélanie TilteFlorent Zoonekynd 2. 1990AeternaLaboratories formation 3. 90/09/12: creation of Aeterna Laboratories by Eric and Luc Dupont Aim:…

1. The future of drug discovery has arrivedReducing development time, cost & riskInvestor Presentation | September 2014 2. 2Critical Outcome Technologies Inc.2 A bioinformatics…

1. 1990AeternaLaboratories formation 2. 90/09/12: creation of Aeterna Laboratories by Eric and Luc Dupont Aim: developing a medicine against cancerFinancial need: creation…

1. www.chamc.co.kr Aspect of Stem Cell-Based Therapies: Insights and Lessons from Ongoing Human Clinical Trials using stem cells Clinical Excellence & Proof of Concept…

1. OTCQB:CTDHOverviewCTD Holdings, Inc. owns and acquires companiesthat develop, market, (and/or sell) productscontaining cyclodextrins (CDs). Cyclodextrinsare rings of glucose…

More than just a potential breakthrough treatment for many cancers April 2015 22 Critical Outcome Technologies Inc. A biopharmaceutical company rapidly developing targeted…

Hyung Min Chung Konkuk University, College of Medicine, Seoul, Korea 2014 MFDS Meeting 2014. 7. 9~10. 2014 MFDS Global Biopharmaceutical Forum Ideal Cell Sources for Stem…

1. 1 Mastering Regulatory Approval in New Orphan Drug Markets Lewis Lau, RAC Independent Regulatory Science Researcher Humber-RAC Work Group Toronto, Canada 2. 2 The views…

Slide 1 GENTA (GNTA) www.genta.com Recent stock price: 12.44 (2/17/04 close) 52-wk range: 5.50 – 17.65 Market cap: 923 Mil Diluted EPS: - 0.66 Revenue: 5.2 Mil ttm Expenses:…